 |
|
Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy
Caroline Kertzman, PhD;
David Lee Robinson, PhD;
Irene Litvan, MD
Arch Neurol. 1990;47(12):1346-1350.
Abstract
• We tested patients with progressive supranuclear palsy and control subjects on a task of visuospatial attention. Targets preceded by cues on the same side were termed validly cued; and those on the opposite side, invalidly cued. For all subjects, validly cued targets were responded to faster than those that were invalidly cued. The difference between reaction times for invalidly and validly cued targets, which is hypothesized to measure attentional movement, was significantly increased for the patients. The performance of the controls on certain neuropsychological tests was correlated with their attentional ability. These correlations were altered by progressive supranuclear palsy. Physostigmine treatment of the patients induced a speeding of responses to invalidly cued targets as a function of the duration of the disease. These studies show defects in cognition and attention in patients with progressive supranuclear palsy and demonstrate that physostigmine reduces some of the abnormal visual attentional performance.
Author Affiliations
From the Section on Visual Behavior, Laboratory of Sensorimotor Research, National Eye Institute (Drs Kertzman and Robinson), and the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke (Dr Litvan), National Institutes of Health, Bethesda, Md.
Footnotes
Accepted for publication June 15, 1990.
Reprint requests to Section on Visual Behavior, Laboratory of Sensorimotor Research, National Institutes of Health, Bldg 10, Room 10C101, Bethesda, MD 20892 (Dr Robinson).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia
Hirano et al.
Brain 2010;133:2058-2068.
ABSTRACT
| FULL TEXT
Cholinergic systems in progressive supranuclear palsy
Warren et al.
Brain 2005;128:239-249.
ABSTRACT
| FULL TEXT
Pharmacological Therapy in Progressive Supranuclear Palsy
Kompoliti et al.
Arch Neurol 1998;55:1099-1102.
ABSTRACT
| FULL TEXT
|
